RxDoctor Payments Data

Herminio Garcia-Estrada, MD

Nephrology · Miami, FLNPI 1285636613

Payments from drug & device makers

$7,401in general payments, 2019–2025

Across 40 payments — averaging $185.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$6K
  • AbbVie$450
  • Fresenius USA Marketing, Inc.$371
  • Akebia Therapeutics Inc$205
  • Vifor Pharma, Inc.$145
  • AstraZeneca$96
  • plus $95 from 4 others

What the payments were for

  • Consulting fees$5,87284%
  • Food & beverage$1,05515%
  • Education$250%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,401 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$58,101
Medicare patients
97
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide30$43,858
FarxigaDapagliflozin Propanediol63$39,431
VeltassaPatiromer Calcium Sorbitex22$23,757
ProcritEpoetin Alfa26$22,076
EliquisApixaban16$8,629
Sevelamer Carbonate62$6,316
RetacritEpoetin Alfa-Epbx15$5,277
Calcium Acetate24$2,009
Febuxostat19$1,693
Sodium Polystyrene Sulfonate14$1,027
Labetalol Hcl51$750
Losartan Potassium57$344
Gabapentin22$216
Temazepam17$154
Amitriptyline Hcl11$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$371$43,85830 claims
AstraZenecaFarxiga$96$39,43163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →